CN113260362A - 加波沙朵、加奈索酮和别孕烯醇酮用于治疗运动障碍的用途 - Google Patents

加波沙朵、加奈索酮和别孕烯醇酮用于治疗运动障碍的用途 Download PDF

Info

Publication number
CN113260362A
CN113260362A CN201980087887.3A CN201980087887A CN113260362A CN 113260362 A CN113260362 A CN 113260362A CN 201980087887 A CN201980087887 A CN 201980087887A CN 113260362 A CN113260362 A CN 113260362A
Authority
CN
China
Prior art keywords
hours
pharmaceutically acceptable
gaboxadol
acceptable salt
dystonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980087887.3A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN113260362A publication Critical patent/CN113260362A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980087887.3A 2018-11-05 2019-11-05 加波沙朵、加奈索酮和别孕烯醇酮用于治疗运动障碍的用途 Pending CN113260362A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755674P 2018-11-05 2018-11-05
US62/755,674 2018-11-05
PCT/US2019/059822 WO2020097045A1 (en) 2018-11-05 2019-11-05 Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders

Publications (1)

Publication Number Publication Date
CN113260362A true CN113260362A (zh) 2021-08-13

Family

ID=70460237

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980087887.3A Pending CN113260362A (zh) 2018-11-05 2019-11-05 加波沙朵、加奈索酮和别孕烯醇酮用于治疗运动障碍的用途

Country Status (10)

Country Link
US (2) US20200138785A1 (https=)
EP (1) EP3860595A4 (https=)
JP (1) JP2022511673A (https=)
KR (1) KR20210087952A (https=)
CN (1) CN113260362A (https=)
AU (1) AU2019377074A1 (https=)
CA (1) CA3118688A1 (https=)
IL (1) IL282189A (https=)
MX (1) MX2021005291A (https=)
WO (1) WO2020097045A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077470A (zh) * 2023-02-06 2023-05-09 青岛润昕德生物医药有限公司 一种加奈索酮制剂及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117801047B (zh) * 2023-01-19 2024-12-20 北京华睿鼎信科技有限公司 神经甾体衍生物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20180042903A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858609B2 (en) * 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
US9629853B2 (en) * 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CA2973140C (en) * 2015-02-06 2025-09-16 Marinus Pharmaceuticals, Inc. Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
DK3364993T3 (da) * 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
KR20240157128A (ko) * 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032553A1 (en) * 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20180042903A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077470A (zh) * 2023-02-06 2023-05-09 青岛润昕德生物医药有限公司 一种加奈索酮制剂及其制备方法

Also Published As

Publication number Publication date
US20200138785A1 (en) 2020-05-07
IL282189A (en) 2021-05-31
JP2022511673A (ja) 2022-02-01
EP3860595A1 (en) 2021-08-11
EP3860595A4 (en) 2021-11-10
CA3118688A1 (en) 2020-05-14
MX2021005291A (es) 2021-06-18
AU2019377074A1 (en) 2021-05-13
KR20210087952A (ko) 2021-07-13
US20220110917A1 (en) 2022-04-14
WO2020097045A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
CN119112906A (zh) 用于治疗癫痫性紊乱的方法和组合物
TWI763632B (zh) 用於重症治療時之鎮靜方法及非口服調配物
EP3579826B1 (en) Methods of treating cdkl5 disorders with the compound ov329
CN110996910A (zh) 抑郁障碍的治疗
CN111201022A (zh) 加波沙朵在治疗糖尿病及相关状况中的用途
CN104918619A (zh) 稳定的肠胃外dnj组合物
US20220110917A1 (en) Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
US20220241253A1 (en) Use of gaboxadol in the treatment of substance use disorders
CA2906060A1 (en) Method of treating vitamin b12 deficiency
US20230285369A1 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
HK40121582A (zh) 用於治疗癫痫性紊乱的方法和组合物
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
HK40007677A (en) Methods and compositions for treatment of epileptic disorders
HK40050846A (en) Use of gaboxadol in the treatment of substance use disorders
HK40030383A (en) Use of gaboxadol in the treatment of diabetes and related conditions
HK1256349A1 (zh) 用於在危重监护治疗期间使用的镇静方法和肠胃外制剂
HK40017808A (en) Methods of treating seizure disorders
HK40027257A (en) Treatment of depressive disorders
CN110545809A (zh) 治疗发作性疾病的方法
HK1214956B (zh) 稳定的肠胃外dnj组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210813

WD01 Invention patent application deemed withdrawn after publication